Genmab — Januar 2026

[StockBull]

https://proinvestor.com/boards/125146/$/130704

[ProinvestorNEWS]

Genmab får hævet kursmål til 2300 kr. fra 2000 kr. hos Jyske Bank https://proinvestor.com/investornyt/1403296/genmab-far-haevet-kursmal-til-2300-kr-fra-2000-kr-hos-jyske-bank

[E_L]

TECVAYLI monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide https://www.jnj.com/media-center/press-releases/tecvayli-monotherapy-demonstrates-superior-progression-free-and-overall-survival-versus-standard-of-care-as-early-as-first-relapse-in-patients-with-multiple-myeloma-predominantly-refractory-to-anti-cd38-therapy-and-lenalido

[E_L]

Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? https://www.oncnursingnews.com/view/why-does-rina-s-target-folate-receptor-alpha-in-endometrial-cancer-

[ProinvestorNEWS]

Regnskabets time nærmer sig for C25-selskaberne, og Helge Larsen er meget spændt på, hvordan de selv guider for 2026 - et år, der tegner til at blive meget udfordrende. Han dykker ned i fremtidsudsigterne hos nogle af ProInvestors mest omtalte selskaber. Bla. Maersk, Novo, Genmab, Pandora og GN Store Nord. Kort video: https://proinvestor.com/boards/130714/

[Sukkeralf]

https://finance.yahoo.com/news/latest-global-t-cell-engagers-083000218.html

[Sukkeralf]

Lyder lovende for TCE narkedet fremadrettet

[E_L]

For the Dutch : Dr. Marcel Nijland over epcoritamab met R2 bij R/R folliculair lymfoom https://www.mednet.nl/congres-nieuws/dr-marcel-nijland-over-epcoritamab-met-r2-bij-r-r-folliculair-lymfoom/

[E_L]

NASDAQ TRADE HALT OMXCOP:GMAB HALT NEWS PENDING AT 12:55 PM

[E_L]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-topline-results-epcoritamab-duobodyr-cd3xcd20 Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

[Sukkeralf]

Ikke godt: The study did not demonstrate a statistically significant improvement in overall survival (OS) (HR: 0.96 [95% CI 0.77 to 1.20])

[Solsen]

Det var ærgerligt. Monoterapi er ikke godt nok. Resultatet vil give lidt usikkerhed.

[E_L]

OS indeed disappoints -on the first look. we all know though during what period this trial was conducted, and analysis will have to show how disappointing it really is, or if Covid circumstances led to this result, and other therapies after controll arm relapse which could be a factor...

[E_L]

PFS was a win

[E_L]

the drop seems excessive, but i can understand it, as we don't know the exact additional circumstances

[E_L]

reality is also that mono therapy will not really matter that much going forward , me thinks...

[E_L]

ABBV hardly blinked, but it is offcourse still a small impact on Abbvie

[E_L]

it is a shame this news did not come just before JPM, Jan could have explained possibel causes a bit... we may not hear any comments on it now until Q1 in Feb?

[Solsen]

https://borsen.dk/nyheder/virksomheder/genmab-viser-igen-lovende-kraeftdata-i-nyt-studie?b_source=borsen&b_medium=row_-1&b_campaign=latest_news_1 ???

[perstu]

Både Børsen og Finans har lovende overskrifter - "Genmab viser igen lovende kræftdata..